Richard A. Alm

Biochemistry, Genetics and Molecular Biology · Life Sciences

47h-index9.3kcitations127works22.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Resistance in Bacteria(26), Bacterial Genetics and Biotechnology(19), Bacteriophages and microbial interactions(18), Helicobacter pylori-related gastroenterology studies(15), Bacterial biofilms and quorum sensing(15)

Publications127 total

Highly potent quinoxalinediones inhibit α-hemolysin and ameliorate Staphylococcus aureus lung infections
Cell Host & Microbe·2025· 9 citedOpen Access
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses
The Lancet Microbe·2024· 40 citedOpen Access
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps
Antimicrobial Agents and Chemotherapy·2024· 17 citedOpen Access
Antigenic landscapes on <i>Staphylococcus aureus</i> pore-forming toxins reveal insights into specificity and cross-neutralization
mAbs·2022· 9 citedOpen Access
Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!”
Antimicrobial Agents and Chemotherapy·2022· 2 citedOpen Access
Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.
Oxford University Research Archive (ORA) (University of Oxford)·2022· 221 citedOpen Access
The CARB-X Portfolio of Nontraditional Antibacterial Products
ACS Infectious Diseases·2021· 18 cited
A one health framework to estimate the cost of antimicrobial resistance
Antimicrobial Resistance and Infection Control·2020· 62 citedOpen Access
A One Health framework to estimate the cost of antimicrobial resistance.
Research Square (Research Square)·2020· 1 citedOpen Access
A novel pre-clinical antibacterial pipeline database
PLoS ONE·2020· 11 citedOpen Access
Narrow-Spectrum Antibacterial Agents—Benefits and Challenges
Antibiotics·2020· 64 citedOpen Access
A One Health Framework to Estimate Costs of Antimicrobial Resistance
2020Open Access
Innovation in Antimicrobial Resistance: The CARB-X Perspective
ACS Infectious Diseases·2020· 43 cited
The churn--the paradox of progress
Annual Report·2019· 8 cited
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model
Journal of Antimicrobial Chemotherapy·2017· 23 citedOpen Access
Identification of non-PBP2a resistance mechanisms in<i>Staphylococcus aureus</i>after serial passage with ceftaroline: involvement of other PBPs
Journal of Antimicrobial Chemotherapy·2016· 29 citedOpen Access
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations
Journal of Antimicrobial Chemotherapy·2016· 31 citedOpen Access
Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus
Diagnostic Microbiology and Infectious Disease·2016· 6 cited
Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition
Antimicrobial Agents and Chemotherapy·2016· 33 citedOpen Access
<i>In Vitro</i> Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program
Antimicrobial Agents and Chemotherapy·2015· 41 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

T J Trust(10), Patricia Guerry(10), John S. Mattick(9), Sushmita D. Lahiri(7), Robert E. McLaughlin(6), P. Doig(5), Maria Uria-Nickelsen(4), James Whiteaker(4), T J Trust(4), Michele Johnstone(4), John P. Mueller(4), Michael D. Huband(4), David Bacon(3), Cynthia B. Whitchurch(3), Humphrey Gardner(3), Stewart L. Fisher(3), David E. Ehmann(3), Gregory S. Basarab(3), Amy Kutschke(3), Donald T. Moir(2)